|
Precigen, Inc. (PGen) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Precigen, Inc. (PGEN) Bundle
Unabhängig davon, ob Sie ein Anleger oder Analyst sind, ist dieser (PGEN) DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Ausgestattet mit tatsächlichen Daten von Precigen, Inc. können Sie problemlos Prognosen anpassen und die Auswirkungen sofort beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.7 | 103.2 | 103.9 | 26.9 | 6.2 | 4.1 | 2.7 | 1.8 | 1.2 | .8 |
| Revenue Growth, % | 0 | 13.73 | 0.67359 | -74.09 | -76.87 | -34.14 | -34.14 | -34.14 | -34.14 | -34.14 |
| EBITDA | -137.5 | -70.4 | -84.1 | -66.0 | -89.2 | -3.7 | -2.4 | -1.6 | -1.1 | -.7 |
| EBITDA, % | -151.51 | -68.24 | -80.94 | -245.27 | -1433.35 | -89.84 | -89.84 | -89.84 | -89.84 | -89.84 |
| Depreciation | 16.1 | 15.0 | 8.1 | 7.2 | 6.7 | 1.4 | .9 | .6 | .4 | .3 |
| Depreciation, % | 17.79 | 14.58 | 7.84 | 26.72 | 107.12 | 33.39 | 33.39 | 33.39 | 33.39 | 33.39 |
| EBIT | -153.6 | -85.5 | -92.2 | -73.2 | -95.9 | -3.9 | -2.5 | -1.7 | -1.1 | -.7 |
| EBIT, % | -169.31 | -82.82 | -88.77 | -272 | -1540.47 | -94.32 | -94.32 | -94.32 | -94.32 | -94.32 |
| Total Cash | 75.1 | 100.1 | 115.2 | 56.0 | 62.9 | 3.9 | 2.6 | 1.7 | 1.1 | .7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 26.2 | 20.4 | 2.0 | 13.8 | 1.6 | 1.0 | .7 | .5 | .3 | .2 |
| Account Receivables, % | 28.9 | 19.8 | 1.91 | 51.3 | 25.3 | 25.44 | 25.44 | 25.44 | 25.44 | 25.44 |
| Inventories | 16.1 | 11.4 | 13.3 | .3 | .0 | .3 | .2 | .2 | .1 | .1 |
| Inventories, % | 17.74 | 11.01 | 12.77 | 1.07 | 0 | 8.52 | 8.52 | 8.52 | 8.52 | 8.52 |
| Accounts Payable | 5.5 | 4.6 | 3.1 | 4.1 | 1.7 | .5 | .3 | .2 | .1 | .1 |
| Accounts Payable, % | 6.09 | 4.46 | 3 | 15.12 | 27.73 | 11.28 | 11.28 | 11.28 | 11.28 | 11.28 |
| Capital Expenditure | -37.9 | -7.5 | -7.2 | -4.9 | -1.5 | -.8 | -.5 | -.4 | -.2 | -.2 |
| Capital Expenditure, % | -41.76 | -7.3 | -6.98 | -18.3 | -24.67 | -19.8 | -19.8 | -19.8 | -19.8 | -19.8 |
| Tax Rate, % | 0.47529 | 0.47529 | 0.47529 | 0.47529 | 0.47529 | 0.47529 | 0.47529 | 0.47529 | 0.47529 | 0.47529 |
| EBITAT | -152.9 | -85.4 | -92.1 | -73.0 | -95.4 | -3.9 | -2.5 | -1.7 | -1.1 | -.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -211.4 | -68.3 | -76.1 | -68.6 | -80.1 | -4.4 | -1.9 | -1.2 | -.8 | -.5 |
| WACC, % | 11.75 | 11.75 | 11.75 | 11.75 | 11.75 | 11.75 | 11.75 | 11.75 | 11.75 | 11.75 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -6 | |||||||||
| Present Terminal Value | -3 | |||||||||
| Enterprise Value | -10 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -10 | |||||||||
| Diluted Shares Outstanding, MM | 245 | |||||||||
| Equity Value Per Share | -0.04 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
- Real-World Data: Precigen, Inc. (PGEN)’s financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template calculates Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Pre-Loaded Data: Precigen, Inc.’s (PGEN) historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Instant Results: Observe Precigen, Inc.’s (PGEN) intrinsic value recalculating in real time.
- Clear Visual Outputs: Dashboard charts showcase valuation results and key metrics.
- Built for Accuracy: A professional tool designed for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template containing Precigen, Inc.'s (PGEN) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Precigen, Inc.'s (PGEN) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose This Calculator for Precigen, Inc. (PGEN)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for Precigen, Inc. (PGEN).
- Flexible Inputs: Modify yellow-highlighted cells to explore different financial scenarios for Precigen, Inc. (PGEN).
- In-Depth Analysis: Automatically computes the intrinsic value and Net Present Value for Precigen, Inc. (PGEN).
- Rich Data Sources: Historical and projected data provide reliable foundations for analysis.
- Expert-Level Tool: Perfect for financial analysts, investors, and consultants focusing on Precigen, Inc. (PGEN).
Who Should Use This Product?
- Biotech Students: Explore advanced genetic engineering techniques and apply them using real-world data.
- Researchers: Integrate cutting-edge models into your studies or publications.
- Investors: Evaluate your investment strategies and analyze the market performance of Precigen, Inc. (PGEN).
- Market Analysts: Enhance your analysis with a tailored, ready-to-use valuation model.
- Healthcare Entrepreneurs: Understand how leading biotech firms like Precigen, Inc. (PGEN) are assessed and valued.
What the Template Contains
- Pre-Filled Data: Includes Precigen, Inc.'s (PGEN) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Precigen, Inc.'s (PGEN) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.